Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

Overview
Date Founded

2012

Headquarters

Marina One East Tower,7 Straits View,Suite 12-00,Singapore, Central Singapore 018936

Type of Company

Public

Employees (Worldwide)

250

Industries

Biotechnology

Company Description

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Contact Data
Trying to get in touch with decision makers at Wave Life Sciences Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

General Counsel

Chief Commercial Officer

Chief Medical Officer

Chief Human Resources Officer

Senior Vice President-Corporate Development & Head-Emerging Areas

Senior Vice President-Operations & Business Analytics

Senior Vice President, Drug Discovery

Senior Vice President, Technical Operations

Vice President, Corporate Affairs & Patient Advocacy

Board of Directors

Former General Accounting Manager at Sugen LLC

Founder at RA Capital Management LLC

Founder at LifeMine Therapeutics, Inc.

Chief Executive Officer & Director at Adaptimmune Therapeutics PLC

Chief Operating Officer, Representative Director & Vice President at Shin Nippon Biomedical Laboratories, Ltd.

Chief Executive Officer & Director at Correvio Pharma Corp.

President & Chief Executive Officer at Wave Life Sciences Ltd.

Senior Vice President-Government Affairs & Policy at Global Blood Therapeutics, Inc.

Head, Sobi North America at Swedish Orphan Biovitrum AB

Managing Director at Miura & Associates Management Consultants Pte Ltd.

Paths to Wave Life Sciences Ltd.
Potential Connections via
Relationship Science
You
Wave Life Sciences Ltd.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.

Recent Transactions
Details Hidden

Wave Life Sciences Ltd. issued USD Common Stock

Details Hidden

Wave Life Sciences Ltd. issued USD Ordinary Shares

Details Hidden

Wave Life Sciences Ltd. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onWave Life Sciences Ltd. issued USD Common Stock

Escrow Agent

Advised onWave Life Sciences Ltd. issued USD Common Stock

Underwriter

Advised onWave Life Sciences Ltd. issued USD Common Stock

Professional

Advised onWave Life Sciences Ltd. issued USD Common Stock

Managing Director

Advised onWave Life Sciences Ltd. issued USD Common Stock

Managing Director

Advised onWave Life Sciences Ltd. issued USD Common Stock

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2018
Market Capitalization
$268M
Total Enterprise Value
$1.05B
Earnings Per Share
$-5.06
Revenue
$14.4M
Net Profit
$-147M
EBITDA
$-154M
EBITDAMargin
-1,068%
Total Debt
$0
Total Equity
$81.2M
Enterprise Value Sales
72.91x
TEVNet Income
-7.17x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
353.18%
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Cormorant invests in companies primarily located in North America. The firm targets companies in sectors such as life-science and biotech. It provides financing for early stage capital requirements.

Suppliers
Max Planck Society Publishing | Munich, BV

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of German research institutes publicly funded by the federal and the 16 state governments of Germany. It is named in honor of its former president, theoretical physicist Max Planck. The 82 research institutes of the Max Planck Society (as 2013) conduct basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 17,000 permanent employees, including 5,470 scientists, plus around 4,500 non-tenured scientists and guests. The Max Planck Society has a world-leading reputation as a science & technology research organization, with 32 Nobel Prizes awarded to their scientists, and are generally regarded as the foremost basic research organization in Europe and the world.

The University of Tokyo was established in 1877 as the first national university in Japan. As a leading research university, UTokyo offers courses in essentially all academic disciplines at both undergraduate and graduate levels and conducts research across the full spectrum of academic activity. The University aims to provide its students with a rich and varied academic environment that ensures opportunities for both intellectual development and the acquisition of professional knowledge and skills. To learn more about the University of Tokyo, please visit the pages below.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Ionis Pharmaceuticals, Inc. Pharmaceuticals - Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Wave Life Sciences Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Wave Life Sciences Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Wave Life Sciences Ltd..